Prophylactic effect of citalopram in unipolar, recurrent depression: placebo-controlled study of maintenance therapy.
BACKGROUND
Major depression is highly recurrent. Antidepressant maintenance treatment has proven efficacy against recurrent depression.


OBJECTIVE
Comparison of prophylactic efficacy of citalopram versus placebo in unipolar, recurrent depression.


METHODS
Patients 18-65 years of age with recurrent unipolar major depression (DSM-IV), a Montgomery-Asberg Depression Rating Scale score of > or =22 and two or more previous depressive episodes, one within the past 5 years, were treated openly with citalopram (20-60 mg) for 6-9 weeks and, if responding, continued for 16 weeks before being randomised to double-blind maintenance treatment with citalopram or placebo for 48-77 weeks.


RESULTS
A total of 427 patients entered acute treatment and 269 were randomised to double-blind treatment. Time to recurrence was longer in patients taking citalopram than in patients taking placebo (P:<0.001). Prophylactic treatment was well tolerated.


CONCLUSIONS
Citalopram (20, 40 and 60 mg) is effective in the prevention of depressive recurrences. Patients at risk should continue maintenance treatment at the dose necessary to resolve symptoms in the acute treatment phase.
Privatklinik, CH-3860 Meiringen, Switzerland.
B
B
Hochstrasser
P M
PM
Isaksen
H
H
Koponen
L
L
Lauritzen
F A
FA
Mahnert
F
F
Rouillon
A G
AG
Wade
M
M
Andersen
S F
SF
Pedersen
J C
JC
Swart
R
R
Nil
D000293:Adolescent; D000328:Adult; D000368:Aged; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects / Q000627:therapeutic use*; D015283:Citalopram / Q000009:adverse effects / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy / Q000517:prevention & control*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016016:Proportional Hazards Models; D012008:Recurrence; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*
D018687:Antidepressive Agents, Second-Generation; D015283:Citalopram; D017367:Selective Serotonin Reuptake Inhibitors